NURS 6501 Week 2 Assgnment; ALS Case Study Analysis

How does the SOD1 mutation contribute to Maria’s disease progression, and what cellular mechanisms are involved in ALS pathophysiology? To understand how the SDO1 mutation contributed to Maria’s disease progression, it is important to understand the role of this enzyme. In particular, this enzyme is involved in the breakdown of superoxide radicals. As such, mutations in this gene contributes to the progression of ALS by leading to the production of SOD1 protein that is vulnerable to mis-folding and aggregation, therefore, undermining its role in eliminating superoxide radicals (Berdyński et al., 2022). The accumulation of these radicals has been implicated in several pathophysiological processes associated with ALS. These include increased oxidative stress which damages cellular components, mitochondrial damage and dysfunction, and glutamate excitotoxicity which overstimulates neurons. In addition, SOD1 aggregation disrupts normal axonal transport (Berdyński et al., 2022). What are the key clinical indicators of ALS progression, and how do they correlate with Maria’s worsening symptoms? The key clinical indicators of ALS progression include muscle weakness and cramps, swallowing and breathing problems, and fatigue. These key indicators are consistent with the new symptoms presented by Maria. For instance, difficulties in swallowing liquids resulting to increase choking, aspiration episodes, shortness of breath and muscle weakness and cramping in multiple areas of body are quite indicative of ALS progression. An interplay of genetic and environmental factors contributes to cellular damage that leads to increased neurodegeneration; therefore, explaining the continued progression in muscle weakness and the loss of muscle control (Masrori & Van Damme, 2020). How can healthcare providers balance symptom management with patient autonomy and end-of-life discussions in ALS care? Balancing symptom management with patient autonomy and end-of-life discussions in ALS is of the utmost importance. This requires a high level of patient-centeredness that prioritizes quality of life, shared decision-making, and open communication. Patient- centeredness ought to involve interventions intended to address patient-specific bio- psychosocial needs while open communication ought to involve an accurate sharing of information related to disease progression, the expected prognostic outcomes, and the treatment options available including their risks and benefits. On the other hand, it is important to note that end-of-life care and symptom management interventions ought to be patient-driven. In this regard, is important to provide adequate room for the expression of autonomy. In the same vein, it is important to offer holistic care that also prioritizes emotional comfort. In this regard, it is important to involve family members and mobilize social and emotional support structures. For the sake of ensuring the unique expectations of a client are met, it is also rewarding to have advance directives in the event that the patient is unable to express their desires. References